Literature DB >> 24613277

RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.

Ji-Hun Lim1, Seongsoo Jang1, Chan-Jeoung Park1, Young-Uk Cho1, Je-Hwan Lee2, Kyoo-Hyung Lee2, Jin-Ok Lee3, Jong-Yeon Shin4, Jong-Il Kim4, Jooryung Huh5, Eul-Ju Seo6.   

Abstract

Anaplastic lymphoma receptor tyrosine kinase (ALK) is located on chromosome 2p23; the chromosomal rearrangements of this gene are common genetic alterations, resulting in the creation of multiple fusion genes involved in tumorigenesis. However, the presence of an ALK fusion in myeloid malignancies is extremely rare. We report a case of acute myelomonocytic leukemia in a 31-year-old woman with an unusual rearrangement between RAN-binding protein 2 (RANBP2) and ALK and a karyotype of 45,XX,inv(2)(p23q21),-7[20]. We detected an ALK rearrangement using fluorescence in situ hybridization, identified the ALK fusion partner by using RNA transcriptome sequencing, and demonstrated the RANBP2-ALK fusion transcript by reverse transcriptase--PCR and Sanger sequencing. Immunohistochemistry for ALK showed strong staining of the nuclear membrane in leukemic cells. The patient had an unfavorable clinical course. Our results, together with a literature review, suggest the RANBP2-ALK fusion combined with monosomy 7 may be related to a unique clonal hematologic disorder of childhood and adolescence, characterized by myelomonocytic leukemia and a poor prognosis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALK; RANBP2; acute myelomonocytic leukemia; fusion gene; monosomy 7

Mesh:

Substances:

Year:  2014        PMID: 24613277     DOI: 10.1016/j.cancergen.2013.12.003

Source DB:  PubMed          Journal:  Cancer Genet


  6 in total

1.  Therapeutically Targetable ALK Mutations in Leukemia.

Authors:  Julia E Maxson; Monika A Davare; Samuel B Luty; Christopher A Eide; Bill H Chang; Marc M Loriaux; Cristina E Tognon; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Brian J Druker; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2015-06-01       Impact factor: 12.701

2.  Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene.

Authors:  A Hayashi; R Tanoshima; S-I Tsujimoto; M Yanagimachi; M Takeuchi; K Sasaki; J Ikeda; R Kajiwara; S Ito; H Takahashi
Journal:  Blood Cancer J       Date:  2016-08-05       Impact factor: 11.037

Review 3.  The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Authors:  Mathias Boulanger; Rosa Paolillo; Marc Piechaczyk; Guillaume Bossis
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

4.  Identification of key regulators in prostate cancer from gene expression datasets of patients.

Authors:  Irengbam Rocky Mangangcha; Md Zubbair Malik; Ömer Küçük; Shakir Ali; R K Brojen Singh
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

5.  The association of RAN and RANBP2 gene polymerphisms with Wilms tumor risk in Chinese children.

Authors:  Xiaokai Huang; Jie Zhao; Wen Fu; Jinhong Zhu; Susu Lou; Xiaoqian Tian; Shanshan Chen; Jichen Ruan; Jing He; Haixia Zhou
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

Review 6.  SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.

Authors:  Karolin Eifler; Alfred C O Vertegaal
Journal:  Trends Biochem Sci       Date:  2015-10-22       Impact factor: 13.807

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.